Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Alemtuzumab-based therapy for Secondary Malignant Histiocytosis arising from Pre-B-ALL. Leuk Res Rep 2018;9:5-8



Pubmed ID


Pubmed Central ID




Scopus ID

2-s2.0-85037688019   2 Citations


•Secondary Malignant Histiocytosis (SMH) is an exceedingly rare, life-threatening condition that invariably occurs in the presence of an underlying monoclonal hematologic disorder. Prognosis of SMH remains dismal and there is no established treatment. •We report a case of a patient who developed SMH during induction chemotherapy for his underlying pre-B-ALL, that caused persistently high fevers and was only diagnosed by a marrow while cytopenic in phase 2 induction. He was treated with alemtuzumab-based therapy that reduced the histiocytic infiltration of the bone marrow from 80% to 15% and made him eligible to undergo T-cell replete allogeneic stem transplantation from his sibling. •This report is the first to highlight the role of alemtuzumab, an anti-CD52 monoclonal antibody, in clonal disorders originating from transdifferentiation. •The alemtuzumab-based regimen should be reserved only for carefully selected allogeneic transplant patients.

Author List

Abid MB, Wadera K, Bird JM, Pawade J, Marks DI


Muhammad Bilal Abid MD Assistant Professor in the Medicine department at Medical College of Wisconsin